Floatz Rating
B60/100
Confidence
Indicative
Sponsor
Chulalongkorn University
Modality
Small molecule
Development Phase
Phase 4 / Approved
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
49High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT02435771CT.gov Efficacy Of Ergocalciferol In Adults According To BMI | — | Terminated | — | — | — |
NCT01004354CT.gov Vitamin D Supplementation in Psychiatric Illnesses | — | Completed | — | — | — |
NCT00288873CT.gov Characterization of Hyperparathyroidism and Vitamin D Deficiency in Obesity | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
95High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Vitamin D Deficiency
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Viosterol (this asset) | Chulalongkorn University | Approved | B · 60 |
| Vitamin D | Yale University | P4 | A |
| Metformin | Ain Shams University | P4 | BBB |
| 1,25-dihydroxyvitamin d | University Hospital Rijeka | P4 | BB |
| Letrozole | Umm Al-Qura University | P4 | BB |
| Clomifene | Ain Shams University | P4 | B |
| Colecalciferol | Radboud University Medical Center | P2 | CCC |
| Clomiphene Citrate | Umm Al-Qura University | P1/2 | CC |
| Cysteine | Louisiana State University Health Sciences Center Shreveport | Early P1 | CC |
+8 more in the Vitamin D Deficiency cohort
Other indications for Viosterol
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Secondary Hyperparathyroidism | — | P4 | BB · 64 |
| Impaired Renal Function Disease | — | P3 | B · 61 |
| Essential Hypertension | — | P3 | B · 61 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Viosterol in Vitamin D Deficiency. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 10, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/viosterol-vitamin-d-deficiency
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →